Home » Topics » Regulatory » EMA

EMA
RSS

EMA grants SPK-9001 access to PRIME program for hemophilia B

March 6, 2017

EMA grants PRIME access to givosiran for acute hepatic porphyrias

March 2, 2017

EMA committee hands down positive opinion for 8-week regimen of Viekirax + Exviera

March 1, 2017

EMA committee hands down positive opinion for Varuby

Feb. 27, 2017

EMA committee recommends broadening approval of Darzalex

Feb. 27, 2017

Tafinlar plus Mekinist granted positive opinion in E.U. for BRAF-positive NSCLC

Feb. 27, 2017

EMA CHMP gives positive opinion on ZS-9 for hyperkalemia

Feb. 27, 2017

EMA committee supports conditional marketing approval for Shire's Natpar

Feb. 27, 2017

EMA grants orphan drug designation to LYS-GM101 for the treatment of GM1 gangliosidosis

Feb. 22, 2017

Armetheon receives advice from EMA on pivotal study of oral anticoagulant

Feb. 15, 2017

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...